FMBTD
VYNE icon

First Midwest Bank Trust Division’s VYNE Therapeutics VYNE Stock Holding History

First Midwest Bank Trust Division’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,138
Closed -$471K – 389
2020
Q4 		$471K Buy
+4,138
New +$520K 0.07% 249

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

First Midwest Bank Trust Division's VYNE Position: Q1 2021 in Review

First Midwest Bank Trust Division sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 4,138 shares — an estimated $471K sold.

First Midwest Bank Trust Division first reported a position in VYNE in Q4 2020 and held it in 1 quarter. The position peaked at $471K in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • First Midwest Bank Trust Division reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • First Midwest Bank Trust Division sold 4,138 VYNE Therapeutics shares in Q1 2021, an estimated $471K.
  • First Midwest Bank Trust Division first reported a position in VYNE Therapeutics in Q4 2020 and held it in 1 quarter.
  • First Midwest Bank Trust Division's VYNE Therapeutics position peaked at $471K in Q4 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on First Midwest Bank Trust Division's 13F filing for Q1 2021, filed 15 Apr 2021.